Gateway Wealth Partners LLC Has $1.44 Million Stock Position in Gilead Sciences, Inc. $GILD

Gateway Wealth Partners LLC grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 152.8% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 10,298 shares of the biopharmaceutical company’s stock after acquiring an additional 6,225 shares during the period. Gateway Wealth Partners LLC’s holdings in Gilead Sciences were worth $1,435,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of GILD. Brighton Jones LLC lifted its stake in shares of Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock worth $1,326,000 after acquiring an additional 2,450 shares during the period. Bison Wealth LLC bought a new position in Gilead Sciences during the 4th quarter worth approximately $215,000. Sivia Capital Partners LLC lifted its position in shares of Gilead Sciences by 16.8% in the 2nd quarter. Sivia Capital Partners LLC now owns 4,182 shares of the biopharmaceutical company’s stock worth $464,000 after purchasing an additional 602 shares during the period. Ieq Capital LLC boosted its stake in shares of Gilead Sciences by 12.0% in the 2nd quarter. Ieq Capital LLC now owns 118,695 shares of the biopharmaceutical company’s stock valued at $13,160,000 after purchasing an additional 12,705 shares during the last quarter. Finally, Diversify Advisory Services LLC increased its position in shares of Gilead Sciences by 18.6% during the second quarter. Diversify Advisory Services LLC now owns 4,296 shares of the biopharmaceutical company’s stock worth $516,000 after buying an additional 674 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Up 2.9%

Gilead Sciences stock opened at $134.32 on Wednesday. The company has a market capitalization of $166.77 billion, a PE ratio of 18.30 and a beta of 0.32. Gilead Sciences, Inc. has a 12-month low of $108.46 and a 12-month high of $157.29. The firm’s fifty day moving average is $129.64 and its 200 day moving average is $135.75. The company has a quick ratio of 1.77, a current ratio of 1.97 and a debt-to-equity ratio of 0.89.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported $2.03 EPS for the quarter, topping analysts’ consensus estimates of $1.91 by $0.12. Gilead Sciences had a net margin of 30.99% and a return on equity of 48.19%. The business had revenue of $6.96 billion during the quarter, compared to analysts’ expectations of $6.91 billion. During the same period last year, the company posted $1.81 earnings per share. The business’s quarterly revenue was up 4.4% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at -1.050–0.650 EPS. As a group, sell-side analysts predict that Gilead Sciences, Inc. will post -0.77 EPS for the current fiscal year.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Morgan Stanley maintained an Overweight rating on Gilead and only modestly reduced its price target to $165 from $166, implying substantial potential upside based on the recent trading level. The endorsement supports sentiment toward Gilead’s valuation and outlook. Benzinga analyst update
• Positive Sentiment: Gilead’s shares outperformed the market during the latest session, suggesting investors may be responding to the company’s defensive profile, strong profitability and established product portfolio. Its most recent reported quarter exceeded consensus estimates for both earnings and revenue, providing a supportive backdrop. Gilead Sciences outperforms the market
• Neutral Sentiment: Broader biopharmaceutical industry developments, including digital bioprocessing and prediction-market discussions related to drug research, do not appear to create a direct near-term catalyst for Gilead. Bioprocessing Summit 2026
• Negative Sentiment: Zacks expects Gilead to report a decline in upcoming earnings and says the company lacks the combination of positive earnings revisions and estimates typically associated with a likely earnings beat. This could limit upside or increase volatility ahead of the results. Gilead earnings expectations

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. Rothschild & Co Redburn dropped their target price on shares of Gilead Sciences from $170.00 to $167.00 in a report on Monday, May 11th. The Goldman Sachs Group increased their price target on Gilead Sciences from $125.00 to $130.00 and gave the stock a “neutral” rating in a report on Friday, April 17th. Daiwa Securities Group lowered their price objective on Gilead Sciences from $161.00 to $150.00 and set an “outperform” rating for the company in a research report on Tuesday, May 19th. Leerink Partners downgraded Gilead Sciences from an “outperform” rating to a “market perform” rating and dropped their price objective for the company from $146.00 to $127.00 in a research note on Tuesday, July 21st. Finally, HSBC upgraded Gilead Sciences from a “hold” rating to a “buy” rating and upped their target price for the company from $133.00 to $155.00 in a research report on Monday, July 6th. Twenty-five investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $158.30.

Insider Transactions at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $131.46, for a total transaction of $1,971,900.00. Following the transaction, the chief executive officer directly owned 617,567 shares of the company’s stock, valued at approximately $81,185,357.82. This represents a 2.37% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $125.40, for a total value of $376,200.00. Following the transaction, the chief financial officer directly owned 171,646 shares in the company, valued at approximately $21,524,408.40. This trade represents a 1.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 67,000 shares of company stock valued at $8,687,140 in the last 90 days. 0.30% of the stock is currently owned by corporate insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.